Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancers
Janice Y. Lee(Foghorn Therapeutics (United States)), Kevin Wilson(Blueprint Medicines (United States)), Brandon Antonakos, Bryan Perria, Candace Langan, David Terry(Foghorn Therapeutics (United States)), Nathan A. Brooks(Eli Lilly (United States)), Ronee Baracani(Loxo Oncology at Lilly (United States)), Gabrielle R. Kolakowski(Loxo Oncology at Lilly (United States)), Robert Bondi(Loxo Oncology at Lilly (United States)), Bonita D. Jones, Gereint Sis(Loxo Oncology at Lilly (United States)), Dayo Osimboni(Foghorn Therapeutics (United States)), Zhifang Li(Foghorn Therapeutics (United States)), Ross Wallace(Loxo Oncology at Lilly (United States)), Robert S. Flack, Maralee McVean(Loxo Oncology at Lilly (United States))
Cited by 4
Related Papers
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
|Nature|2016|925
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|397
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
|Nature Reviews Urology|2021|154
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
|Molecular Cancer Therapeutics|2013|121